Search

A review of the 2025 Medicare Advantage plans available for individual enrollment shows that the total number of plans declined by 7% (from 3,959 to 3,699). The average Medicare beneficiary will have the option of 34 Medicare Advantage prescription drug (MA-PD) plans in 2025, just 2 fewer than the 36 options available in 2024. Since 2018, the number of plans available to the average beneficiary has doubled.

In this column, KFF president and CEO Drew Altman explores why health costs weigh heavily among voters’ economic concerns, even in an election where health was not a flashpoint. The need to reframe health as a pocketbook issue for voters will be central to the competition for the votes of working class Latino voters, two groups very focused on the cost of living.

This tracker provides an overview of state laws/policies restricting minor access to gender affirming care and any associated litigation by state, identifying which groups of people are impacted in addition to minors, the types of penalties providers face, the status of legal challenges, and other key information.

This tracker provides up-to-date data on federal Ending the HIV Epidemic (EHE) funding, including an overview of funding mechanisms by year, agency, grant mechanism, and jurisdiction. It will be updated over time.

This explainer provides an overview of the federal “Ending the HIV Epidemic” initiative and explores issues that might mitigate or facilitate its success.

Over the past 18 months, there has been a rapid increase in the number of states that have enacted laws and other policies that prohibit or restrict minor access to gender affirming care. This policy watch summarizes state policy developments aimed at restricting minor access to gender affirming care as well as the litigation challenging it. as of January 30, 2024.

This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.

Juliette Cubanski is deputy director of the Program on Medicare Policy at KFF, where she has been conducting research and analysis on Medicare policy issues since 2004. Dr. Cubanski leads work on Medicare prescription drug coverage and related policy issues, including the examination of trends in the Medicare Part D…